Research programme: Neuroprotectin D1 - Anida PharmaAlternative Names: NPD1 - Anida Pharma; Protectin D1
Latest Information Update: 03 Oct 2013
At a glance
- Originator Anida Pharma
- Developer ALS Therapy Development Institute; Anida Pharma
- Class Docosahexaenoic acids; Small molecules
- Mechanism of Action Apoptosis inhibitors; MTOR protein modulators; Proto oncogene protein c akt modulators; Proto-oncogene protein c-bcl-2 modulators; Reactive oxygen species inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Hearing loss; Parkinson's disease